Literature DB >> 34169384

miR-181b-5p Promotes the Progression of Cholangiocarcinoma by Targeting PARK2 via PTEN/PI3K/AKT Signaling Pathway.

Zhe-Long Jiang1,2, Fu-Xing Zhang3, Li-Zhi Lv4,5, Hong-Liang Zhan3, He-Jun Yang1,2, Si-Yu Zhang3, Zhao-Hui Liu3, Yi Jiang1,2, Rui-Sheng Ke6.   

Abstract

This study combined with bioinformatics analysis and investigated the expression pattern of miR-181b-5p, as well as explored its role and mechanism in cholangiocarcinoma (CCA or CHOL). Several bioinformatics databases were used to analyze the expression of miR-181b and the enrichment of miR-181b in biological activities and biological pathways in CCA. The RT-qPCR analysis was used to examine the expression levels of miR-181b-5p. A receiver operation characteristics (ROC) curve analysis and the Kaplan-Meier survival assay were conducted to validate the diagnostic and prognostic implication of miR-181b-5p. Cell experiments were used to explore the possible functional role of miR-181b-5p in CCA progression. The bioinformatics assay was used to predict the target gene of miR-181b-5p and Western blot was used to confirm the related signaling pathway. The bioinformatics analysis results suggest that miR-181b-5p was highly expressed in cholangiocarcinoma and its expression was negatively related to PARK2 expression in CCA tissues. miR-181b-5p expression in the serum and tissues was upregulated and associated with lymph node metastasis and TNM stage. Increased expression of miR-181b-5p had relatively high diagnostic accuracy and showed poor prognosis in CCA patients. In addition, miR-181b-5p overexpression enhanced cell proliferation, migration, and invasion by targeting PARK2. Overexpression of miR-181b-5p activated the PI3K/AKT signaling pathway, while knockdown of miR-181b-5p suppressed the signaling pathway. Increased expression of miR-181b-5p in CCA may be a potential diagnostic or/and prognostic indicator for CCA patients. The present data indicated miR-181b-5p acted as an oncogene in CCA through promoting tumor cell proliferation, migration, and invasion of CCA via the PTEN/PI3K/AKT signaling pathway by targeting PARK2, which might be a promising therapeutic target or biomarker for CCA.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Bioinformatics analysis; Cholangiocarcinoma; Diagnosis and prognosis; Molecular mechanism; miR-181b-5p

Mesh:

Substances:

Year:  2021        PMID: 34169384     DOI: 10.1007/s10528-021-10084-5

Source DB:  PubMed          Journal:  Biochem Genet        ISSN: 0006-2928            Impact factor:   1.890


  28 in total

Review 1.  Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?

Authors:  Witold Filipowicz; Suvendra N Bhattacharyya; Nahum Sonenberg
Journal:  Nat Rev Genet       Date:  2008-02       Impact factor: 53.242

2.  Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.

Authors:  Jianjiong Gao; Bülent Arman Aksoy; Ugur Dogrusoz; Gideon Dresdner; Benjamin Gross; S Onur Sumer; Yichao Sun; Anders Jacobsen; Rileen Sinha; Erik Larsson; Ethan Cerami; Chris Sander; Nikolaus Schultz
Journal:  Sci Signal       Date:  2013-04-02       Impact factor: 8.192

3.  microRNA-181b targets MLK2 in HL-60 cells.

Authors:  Hong Chen; Qun Chen; Ming Fang; Yan Mi
Journal:  Sci China Life Sci       Date:  2010-02-12       Impact factor: 6.038

4.  Increased Expression of miR-29a and Its Prognostic Significance in Patients with Cholangiocarcinoma.

Authors:  Yingbin Deng; Yuxin Chen
Journal:  Oncol Res Treat       Date:  2017-01-25       Impact factor: 2.825

5.  miR-181b as a potential molecular target for anticancer therapy of gastric neoplasms.

Authors:  Jian-Xin Guo; Qing-Song Tao; Peng-Rong Lou; Xiao-Chun Chen; Jun Chen; Guang-Bo Yuan
Journal:  Asian Pac J Cancer Prev       Date:  2012

Review 6.  The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.

Authors:  Amancio Carnero; Carmen Blanco-Aparicio; Oliver Renner; Wolfgang Link; Juan F M Leal
Journal:  Curr Cancer Drug Targets       Date:  2008-05       Impact factor: 3.428

7.  PARK2 loss promotes cancer progression via redox-mediated inactivation of PTEN.

Authors:  Amit Gupta; Sara Anjomani-Virmouni; Nikos Koundouros; George Poulogiannis
Journal:  Mol Cell Oncol       Date:  2017-05-19

8.  LncRNA CCAT1 Promotes Colorectal Cancer Tumorigenesis Via A miR-181b-5p/TUSC3 Axis.

Authors:  Si Chen; Yan Liu; Yuanyuan Wang; Zhaoping Xue
Journal:  Onco Targets Ther       Date:  2019-11-05       Impact factor: 4.147

9.  PARK2 Depletion Connects Energy and Oxidative Stress to PI3K/Akt Activation via PTEN S-Nitrosylation.

Authors:  Amit Gupta; Sara Anjomani-Virmouni; Nikos Koundouros; Maria Dimitriadi; Rayman Choo-Wing; Adamo Valle; Yuxiang Zheng; Yu-Hsin Chiu; Sameer Agnihotri; Gelareh Zadeh; John M Asara; Dimitrios Anastasiou; Mark J Arends; Lewis C Cantley; George Poulogiannis
Journal:  Mol Cell       Date:  2017-03-16       Impact factor: 19.328

10.  PARK2 Suppresses Proliferation and Tumorigenicity in Non-small Cell Lung Cancer.

Authors:  Huijie Duan; Zhong Lei; Fei Xu; Tao Pan; Demin Lu; Peili Ding; Chunpeng Zhu; Chi Pan; Suzhan Zhang
Journal:  Front Oncol       Date:  2019-08-23       Impact factor: 6.244

View more
  3 in total

1.  Overexpression of ST7-AS1 Enhances Apoptosis and Inhibits Proliferation of Papillary Thyroid Carcinoma Cells Via microRNA-181b-5p-Dependent Inhibition Tripartite Motif Containing 3.

Authors:  Yuan Zhao; Xiaoyun Feng; Yonggang Zhao; Huijuan Yang; Chunjie Zhang
Journal:  Mol Biotechnol       Date:  2022-08-27       Impact factor: 2.860

2.  Identification and Validation of miRNA-TF-mRNA Regulatory Networks in Uterine Fibroids.

Authors:  Xiaotong Peng; Yanqun Mo; Junliang Liu; Huining Liu; Shuo Wang
Journal:  Front Bioeng Biotechnol       Date:  2022-03-22

3.  A Four-MicroRNA Panel in Serum as a Potential Biomarker for Screening Renal Cell Carcinoma.

Authors:  Rongkang Li; Chong Lu; Xinji Li; Xuan Chen; Guocheng Huang; Zhenyu Wen; Hang Li; Lingzhi Tao; Yimin Hu; Zhengping Zhao; Zebo Chen; Yongqing Lai
Journal:  Front Genet       Date:  2022-07-22       Impact factor: 4.772

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.